Digital Look

Welcome to Digital Look++,
you are not logged in

Shield Therapeutics (STX)

Pharma and Biotech

1.23p

Trade now with Barclays Stockbrokers

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Jun-23	Interim	4.33	(11.79)	(2.00)¢	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-18	11.88	(5.15)	(1.89)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-19	0.72	(9.07)	(7.55)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-20	10.39	(1.89)	(1.89)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	1.52	(19.91)	(10.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	4.47	(40.08)	(17.00)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-23	13.67	(24.61)	(3.92)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	43.45	(12.77)	(1.87)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-25	85.83	7.93	0.43p	2.9	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.